Organization | Kamuzu Central Hospital

Kamuzu Central Hospital Report issue

Academic/Hospital Phase 3

Founded: Lilongwe Malawi (1977)

Organization Overview

First Clinical Trial

2004

NCT00164736

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Kamuzu Central Hospital | Kamuzu Central Hospital, Lilongwe, Malawi

Active Ingredients

Drugs in Phase 3 Trials (9)

dolutegravir (tivicay) (1 trial)

efavirenz (sustiva) (1 trial)

emtricitabine (emtriva) (2 trials)

lamivudine (epivir) (1 trial)

lopinavir (Kaletra) (1 trial)

nevirapine (viramune) (1 trial)

ritonavir (Norvir) (1 trial)

tenofovir (viread) (2 trials)

zidovudine (retrovir) (1 trial)

Drugs in Other Trials (1)

raltegravir (isentress) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 3)

HIV Infections (Phase 3)

Infections (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 10